Loading
U S Physical Therapy INC /nv Stock: price and insider trades · United States
1 insider bought €408 of shares over the last 90 days, the latest filed 14 Sept 2026.
U S Physical Therapy INC /nv: what insiders have been doing
U S Physical Therapy INC /nv is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). 10 insiders have disclosed 20 filings since 18 October 2025.
On the market, 2 insiders bought (3 purchases totalling €240k) while 2 insiders sold (4 sales totalling €430k). On balance, insiders were net sellers of €190k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a purchase of €239k from Gilmartin Kathleen A, disclosed on 24 November 2025. Those buying include 2 senior executives.
The clock since the last published purchase (14 September 2026) now reads 34 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
With 20 filings in twelve months, the company is more active than the median of 19 filings across the 5,810 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed 13 purchases and 75 sales. The 10-K for the year ended 31 December 2025 shows 781.0 m USD of revenue and 39.6 m USD of net income and a dividend of 1.80 USD per share.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
163
Thresholds
n/a
Buy Volume
€1M
13 ops. · all time
Sell Volume
€13M
75 ops. · all time
Who traded when
BuySaleGraham D. Reeve8 sales
Eric Joseph Williams3 sales
Nancy Ham3 sales
Carey P. Hendrickson2 sales
Peter Francis Minan2 buys
Bernard A. Harris Jr.1 sale
+4 other insiders
Since the insiders bought
- +12.7%Entry US$74.16 · Close at T+90 US$83.55
- +19.4%Entry US$77.96 · Close at T+365 US$93.12
- +21.3%Entry US$90.37 · Close at T+365 US$109.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,860 of 24,148 companies
41.5
score / 100
Value47
Quality36
FCF yld4.8%
Earn yld1.2%
EV/EBITDA14.5x
ROE6.5%
Gross mgn19%
Net mgn1.9%
Debt/EBITDA2.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$85.44
Analyst consensus
6 analysts1.86/5
US$95.00Target US$97.00(+14%)US$100.00
Income statement
RevenueUS$781M
Gross profitUS$149.7M19% margin
EBITDAUS$109.7M14% margin
Net incomeUS$15.1M4.0% margin
Valuation
PER (trailing)474.7x
PER (forward)25.5x
P/Book2.8x
Beta1.11
Balance sheet & cash
Market capUS$1.3B
Total debtUS$315.2M
Free Cash FlowUS$61M
Debt / Equity50%
Profitability & ownership
ROE6.5%
ROA4.1%
% insiders2.6%
% institutions111.4%
Last declaration on 2 October 2026
Declarations163 total
1,210 shares0Common StockSEC:0001193125-26-412265:0
6,831 shares0Common StockSEC:0001193125-26-391910:0
0.87 shares@ US$66.5012.2% of flowCommon StockSEC:0001193125-26-390608:0
Canonical exit: 10 Sept 2026 (T+90)
5.27 shares@ US$79.000.0000% mcap87.8% of flowCommon StockSEC:0001193125-26-390608:1
Canonical exit: 10 Dec 2026 (T+90)
40 shares@ US$78.000.0002% mcap55.5% of flowCommon StockSEC:0001193125-26-363894:0
450 shares@ US$78.000.0028% mcap2.3% of flowCommon StockSEC:0001193125-26-363890:0
762 shares@ US$78.000.0047% mcap1.6% of flowCommon StockSEC:0001193125-26-363888:0
714 shares@ US$78.000.0044% mcap6.2% of flowCommon StockSEC:0001193125-26-363896:0
40 shares@ US$62.240.0002% mcap44.5% of flowCommon StockSEC:0001193125-26-277664:0
662 shares@ US$78.861.4% of flowCommon StockSEC:0001193125-26-104315:0
1,807 shares@ US$82.254.1% of flowCommon StockSEC:0001193125-26-102296:0
10,000 shares0Common StockSEC:0001193125-26-100453:0
3,000 shares@ US$81.6416.0% of flowCommon StockSEC:0001193125-26-098618:0
25,000 shares0Common StockSEC:0001193125-26-072717:0
15,000 shares0Common StockSEC:0001193125-26-072715:0
10,000 shares0Common StockSEC:0001193125-26-072703:0
10,000 shares0Common StockSEC:0001193125-26-072647:0
10,000 shares0Common StockSEC:0001193125-26-072630:0
743 shares@ US$71.011.5% of flowCommon StockSEC:0001193125-25-297192:0
4,000 shares@ US$69.0030.4% of flowCommon StockSEC:0001193125-25-293697:0
Canonical exit: 18 Feb 2026 (T+90)
1,000 shares@ US$85.259.5% of flowCommon StockSEC:0000950170-25-113554:0
2,000 shares@ US$83.535.1% of flowCommon StockSEC:0000950170-25-113254:0
698 shares@ US$86.1118.2% of flowCommon StockSEC:0000950170-25-111251:0
763 shares@ US$84.971.8% of flowCommon StockSEC:0000950170-25-110761:0
25 of 163 declarations
About U S Physical Therapy INC /nv
U.S. Physical Therapy, Inc. (NYSE, NYSE Texas: USPH) is a U.S.-based healthcare services company focused on outpatient rehabilitation and industrial injury prevention. Headquartered in Houston, Texas, United States, the company was founded in 1990 and has grown through a partnership-oriented model that combines owned clinics with locally managed operating relationships. Today, USPH operates a broad national network of outpatient physical therapy clinics across numerous U.S. states, giving it meaningful geographic diversification and exposure to a large, fragmented market.
USPH’s business is organized into two reportable segments. The core outpatient physical therapy segment provides preventive and post-operative care, treatment for orthopedic and sports-related injuries, rehabilitation for injured workers, and therapy for certain neurologic conditions. Its industrial injury prevention segment serves employer clients on site, offering injury-prevention programs, rehabilitation support, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. This dual-platform structure is strategically important: it broadens revenue streams, deepens relationships with employers and healthcare networks, and gives the company exposure to both patient-driven and B2B healthcare demand.
Read moreShow less
From a competitive standpoint, USPH holds a solid position in a highly fragmented outpatient therapy industry where many local practices remain independent. Scale matters in this sector, and USPH has long used acquisitions as a key growth lever. Recent company announcements show that this strategy remains active: in 2025 and 2026, USPH completed and announced several acquisitions of multi-clinic physical therapy practices and an industrial injury prevention business, while also expanding through strategic alliances with major hospital systems. That pattern suggests a continued emphasis on disciplined consolidation, expanding clinical reach, and strengthening referral relationships.
For investors, USPH presents a relatively resilient healthcare services profile supported by recurring rehabilitation demand, employer-focused occupational health services, and a proven acquisition playbook. The company’s recent disclosures also indicate ongoing investor communications through earnings releases and conference presentations, underscoring management’s focus on execution and capital allocation. In short, U.S. Physical Therapy is a niche but sizeable U.S. healthcare operator listed on the NYSE, with a hybrid model that combines outpatient care delivery and industrial injury prevention services, and with continued room for growth through selective acquisitions and network expansion.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
